Cholangiocarcinoma (CCA) is a rare type of bile duct cancer, and it’s the second most common primary liver cancer in the world. Unfortunately, patients with CCA historically have limited treatment options and are often diagnosed at a late or advanced stage when the prognosis is poor.
To create an impactful animation that raises awareness of CCA and its impact on patients, emphasising the importance of molecular testing as a key to unlocking new treatment options.
Launched at the AMMF annual conference by Prof John Bridgewater, the animation has now seen further success at both Incyte’s Pemazyre launch meeting and the British Association of the Study of the Liver conference. As well as providing a vital source of information for CCA patients, feedback also praised how easy the information found in the animation was to digest for newly diagnosed patients.
Molecular profiling is such a complex topic. Therefore, it was paramount to keep the animation simple, allowing the audience to easily relate to the content without binding them to the science.
“What a great job – huge thanks to everyone involved. I’m really excited to think we have this resource for our CCA patients now – and that we will be showing it at AMMF’s conference.” – Helen Morement, CEO of AMMF